Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T21:37:03.471Z.
Calculation as of: 2026-10-06T21:37:03.471Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0d034b685c23fadaea9476ccc197406393d04780d3c67e2351ab6b6412cf62fb
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$58.44M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$62.78M
EBITDA Yield
N/A
TTM Avg
0.88%
3Y Avg
0.88%
5Y Avg
0.88%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Fractyl Health, Inc. (GUTS) | $60.42M | N/A | N/A | N/A | N/A |
| Oncolytics Biotech Inc. (ONCY)vs › | $60.02M | N/A | N/A | N/A | N/A |
| Xilio Therapeutics, Inc. (XLO)vs › | $59.18M | N/A | N/A | N/A | N/A |
| PDS Biotechnology Corporation (PDSB)vs › | $58.44M | N/A | N/A | N/A | N/A |
| Adicet Bio, Inc. (ACET)vs › | $58.43M | N/A | N/A | N/A | N/A |
| MiNK Therapeutics, Inc. (INKT)vs › | $58.29M | N/A | N/A | N/A | N/A |
| RenovoRx, Inc. (RNXT)vs › | $62.62M | N/A | N/A | N/A | N/A |
| Kalaris Therapeutics Inc (KLRS)vs › | $58.06M | N/A | N/A | N/A | N/A |
| Heron Therapeutics, Inc. (HRTX)vs › | $62.78M | N/A | 0.88% | 0.88% | 0.88% |
| InterCure Ltd. (INCR)vs › | $63.02M | N/A | 13.59% | 8.25% | 8.86% |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
